CN112759552A - Synthesis method of semetinib - Google Patents
Synthesis method of semetinib Download PDFInfo
- Publication number
- CN112759552A CN112759552A CN202011643562.XA CN202011643562A CN112759552A CN 112759552 A CN112759552 A CN 112759552A CN 202011643562 A CN202011643562 A CN 202011643562A CN 112759552 A CN112759552 A CN 112759552A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- reaction
- room temperature
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001308 synthesis method Methods 0.000 title description 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 74
- KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims description 117
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 48
- 238000003756 stirring Methods 0.000 claims description 37
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 30
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 239000007787 solid Substances 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 21
- 238000000967 suction filtration Methods 0.000 claims description 21
- 239000012295 chemical reaction liquid Substances 0.000 claims description 17
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 239000012065 filter cake Substances 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 13
- 239000012043 crude product Substances 0.000 claims description 10
- 229940125904 compound 1 Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 229940125782 compound 2 Drugs 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 229940126214 compound 3 Drugs 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000004537 pulping Methods 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 14
- 230000015572 biosynthetic process Effects 0.000 abstract description 13
- 239000000376 reactant Substances 0.000 abstract description 11
- 238000000926 separation method Methods 0.000 abstract description 4
- 238000010189 synthetic method Methods 0.000 abstract description 3
- 239000007795 chemical reaction product Substances 0.000 abstract description 2
- 238000004440 column chromatography Methods 0.000 abstract description 2
- 230000011987 methylation Effects 0.000 abstract description 2
- 238000007069 methylation reaction Methods 0.000 abstract description 2
- 238000007363 ring formation reaction Methods 0.000 abstract description 2
- 238000007039 two-step reaction Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 description 8
- 239000002699 waste material Substances 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000036632 reaction speed Effects 0.000 description 3
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to a synthetic method of sematinib. The invention creatively adopts diethoxymethane as a ring-closing reactant, combines the two-step reaction of ring-closing reaction and methylation into one step, has high yield and reduces the reaction steps. The synthetic route of the invention obtains the semetinib through three-step reaction synthesis, the post-treatment of the synthetic method does not need column chromatography separation, and the reaction product is directly separated out and dried.
Description
Technical Field
The invention relates to the technical field of medicines, and in particular relates to a synthetic method of MEK1/2 inhibitor semetinib.
Background
The anti-tumor drug semetinib (Selumetinib) is an oral, selective potent MEK1/2 inhibitor. On 10/4/2020, the FDA officially approved the simetinib capsule from the company asikang for use as a drug for the treatment of type 1 neurofibromatosis and plexiform neurofibromatosis in pediatric patients. The structure of the sematinib is a compound shown as a formula I:
currently, the synthesis method of sematinib still needs to be improved.
Disclosure of Invention
The present invention is directed to solving, at least to some extent, one of the technical problems in the related art. Therefore, the invention aims to provide a method for synthesizing the sematinib, which has the advantages of few reaction steps of a synthetic route, simple and convenient separation, high total reaction yield, convenient process operability and easy industrial production.
In one aspect of the invention, the invention provides a method for synthesizing sematinib. According to an embodiment of the invention, the method comprises:
(1) contacting a compound represented by formula 1 with diethoxymethane, and pyridine, so as to obtain a compound represented by formula 2;
(2) contacting the compound represented by formula 2 with LiOH to obtain a compound represented by formula 3;
(3) contacting the compound shown as the formula 3 with the compound shown as the formula 4 so as to obtain the compound of the formula I, namely the sematinib.
The inventor finds that by utilizing the synthesis preparation method, the compound of the formula I, namely the semetinib, can be quickly and effectively prepared. The method adopts the available compound 1 as an initial raw material, and synthesizes a target molecule, namely the compound sematinib shown in formula I, through three steps of reactions of amino and carboxyl condensation after ring closure and demethylation protecting group.
The term "contacting" as used herein is to be understood broadly and can be any means that enables a chemical reaction of at least two reactants, such as mixing the two reactants under appropriate conditions. The reactants to be contacted may be mixed with stirring as necessary, and thus, the type of stirring is not particularly limited, and may be, for example, mechanical stirring, that is, stirring under the action of a mechanical force.
Herein, a "compound of formula N" is also sometimes referred to herein as "compound N", where N is any integer from 1 to 4, e.g., "compound of formula 2" may also be referred to herein as "compound 2".
The terms "first", "second" and "first" are used herein for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. In the description of the present invention, "a plurality" means two or more unless specifically defined otherwise.
According to embodiments of the present invention, the above-described methods for preparing the compound of formula 2, the compound of formula 3, and the compound of formula I may further have at least one of the following additional features:
the chemical reactions described herein may be performed according to any method known in the art, according to embodiments of the present invention. The source of the raw materials for preparing the compound represented by formula 2, the compound represented by formula 3, and the compound represented by formula I is not particularly limited, and may be prepared by any known method or may be commercially available.
According to an embodiment of the present invention, in step (1), the contacting manner of the compound represented by formula 1 with diethoxymethane, and pyridine is not particularly limited. Therefore, the contact efficiency of the compound shown in the formula 1 with diethoxymethane and pyridine can be improved, the reaction speed is increased, and the efficiency of preparing the compound shown in the formula 2 by using the method is further improved.
According to an embodiment of the invention, inThe step (1) comprises the following steps: at room temperature, compound 1 and CH3CN is mixed, stirred and H is slowly added2And O, adding diethoxymethane, heating to keep the temperature at 55-65 ℃ for reacting for 2.5-3.5 hours, then slowly adding pyridine, continuously keeping the temperature at 55-65 ℃ for reacting for 8-15 min, cooling the reaction liquid to room temperature, allowing a large amount of white solid to appear in the reaction liquid, performing suction filtration and drying to obtain the compound shown in the formula 2, wherein the compound shown in the formula 2 can be directly used for the next reaction without purification. Thus, the efficiency of preparing the compound represented by formula 2 by the method can be further improved.
According to an embodiment of the present invention, in step (1), the molar ratio of the compound represented by formula 1 to diethoxymethane and pyridine is 1: (1.0-1.2): (1.8-2.5).
According to an embodiment of the present invention, in step (1), it is preferable that the molar ratio of the compound represented by formula 1 to diethoxymethane and pyridine is 1: 1.05: 2, the utilization rate of reactants is high, raw materials and actual waste are not caused, and the yield of the target compound is high.
According to a specific embodiment of the present invention, in the step (1), the following steps are included: compound 1(5.0g,12.87mmol) and CH were added at room temperature3CN (30mL) was mixed, stirred, and H was added slowly2O (5mL), diethoxymethane (1.41g,13.51mmol) is added, the mixture is heated and kept at 60 ℃ for reaction for 3 hours, then pyridine (2.036g,25.74mmol) is slowly added, the mixture is kept at 60 ℃ for reaction for 10 minutes, the reaction liquid is cooled to room temperature, a large amount of white solid appears in the reaction liquid, the compound shown in the formula 2 is obtained through suction filtration and drying, the white solid is obtained, the yield is 5.1g, the yield of crude products is 96.1%, and the crude products are directly used for the next reaction without purification. Therefore, the utilization rate of the reactants is high, the waste of raw materials and reality is avoided, and the yield of the target compound is high.
According to an embodiment of the present invention, in the step (2), the contact manner of the compound represented by formula 2 with LiOH is not particularly limited. Therefore, the contact efficiency of the compound shown in the formula 2 and LiOH can be improved, the reaction speed is increased, and the efficiency of preparing the compound shown in the formula 3 by using the method is further improved.
According to an embodiment of the present invention, in the step (2), the following steps are included: adding the compound 2 into THF under stirring at room temperature, slowly adding LiOH solution, heating to 36-45 ℃, stirring for reaction, cooling the reaction liquid to room temperature after the reaction is finished, removing THF under reduced pressure, slowly adding dilute hydrochloric acid to adjust the pH value to 6, performing suction filtration, and drying to obtain the compound shown in the formula 3. Thus, the efficiency of preparing the compound represented by formula 3 using this method can be further improved.
According to the embodiment of the invention, in the step (2), the compound shown in the formula 2 is contacted with LiOH at 36-45 ℃, and the reaction is carried out for 1.5-2.5 hours under stirring; the compound represented by formula 2 is contacted with LiOH, preferably at 40 ℃, and the reaction is stirred for 2 hours.
According to an embodiment of the present invention, in the step (2), the molar ratio of the compound represented by formula 2 to LiOH is 1: (1.8-2.3).
According to an embodiment of the present invention, in the step (2), it is preferable that the molar ratio of the compound represented by formula 2 to LiOH is 1: 2, the utilization rate of reactants is high, raw materials and actual waste are not caused, and the yield of the target compound is high.
According to a specific embodiment of the present invention, in the step (2), the following steps are included: compound 2(3.5g,8.482mmol) was added to THF (35mL) at room temperature with stirring, a 2M LiOH solution containing LiOH (407mg,17mmol) was slowly added thereto, the temperature was raised to 40 ℃ and the reaction was stirred for 2 hours, after completion of the reaction, the reaction solution was cooled to room temperature, THF was removed under reduced pressure, 2M dilute hydrochloric acid was slowly added to adjust pH to 6, suction filtration was performed, and drying was performed to obtain the compound represented by formula 3 as a white solid in an amount of 3.20g with a yield of 94.7%. Therefore, the utilization rate of the reactants is high, the waste of raw materials and reality is avoided, and the yield of the target compound is high.
According to an embodiment of the present invention, in step (3), the manner of contacting the compound represented by formula 3 with the compound represented by formula 4 is not particularly limited. Therefore, the efficiency of contacting the compound shown in the formula 3 with the compound shown in the formula 4 can be improved, the reaction speed is increased, and the efficiency of preparing the compound shown in the formula I by using the method is further improved.
According to an embodiment of the present invention, in the step (3), the following steps are included: at room temperature, uniformly mixing and stirring the compound 3, the compound 4 and DMF, then dropwise adding N, N-Diisopropylethylamine (DIPEA), keeping at room temperature, stirring for reaction, cooling the reaction liquid to room temperature after the reaction is finished, and adding H2And O, stirring for 10min, then carrying out suction filtration, pulping and washing a filter cake by using an appropriate amount of acetone, and then filtering and drying the filter cake to obtain the compound shown in the formula I. Therefore, the efficiency of preparing the compound shown in the formula I by using the method can be further improved.
According to the embodiment of the invention, in the step (3), the compound shown in the formula 3 is contacted with the compound shown in the formula 4 and DIPEA at room temperature, and the stirring reaction is carried out for 1.5-2.5 hours; the compound represented by formula 3 is preferably contacted with the compound represented by formula 4 and DIPEA at room temperature, and the reaction is stirred for 2 hours.
According to an embodiment of the present invention, in the step (3), the molar ratio of the compound represented by formula 3 to the compound represented by formula 4, and DIPEA is 1: (1.0-1.2): (1.0-1.5).
According to the embodiment of the present invention, in the step (3), the molar ratio of the compound represented by the formula 3 to the compound represented by the formula 4 and DIPEA is preferably 1:1.1:1.2, so that the utilization rate of the reactants is high, the raw materials and the actual waste are not caused, and the yield of the target compound is high.
According to a specific embodiment of the present invention, in the step (3), the following steps are included: mixing and stirring compound 3(2.0g,5mmol), compound 4(424mg,5.5mmol) and DMF (20mL) at room temperature, adding DIPEA (775.5mg,6mmol) dropwise, stirring at room temperature for reaction for 2H, cooling the reaction solution to room temperature after the reaction is finished, and adding H2And O (60mL), stirring for 10min, performing suction filtration, pulping and washing a filter cake by using an appropriate amount of acetone, and filtering and drying the filter cake to obtain the compound shown in the formula I, wherein the white solid is a white solid, the yield is 2.10g, and the HPLC purity is 99.6%. Therefore, the utilization rate of the reactants is high, the waste of raw materials and reality is avoided, and the yield of the target compound is high.
According to embodiments of the present invention, synthetic routes to compounds of formula I can be as follows:
the invention has the beneficial effects that:
(1) the invention provides a method for synthesizing and preparing the sematinib, which has the advantages of few reaction steps of a synthesis route, simple and convenient separation, high total reaction yield, convenient process operability and easy industrial production. The route of the invention adopts the available compound 1 as the starting material, and the target compound, namely the semetinib, is synthesized through three steps of reactions, namely, amino condensation reaction and carboxyl condensation reaction after ring closure and demethylation of protecting groups. By utilizing the synthesis preparation method, the compound of the formula I, namely the sematinib, can be quickly and effectively prepared.
(2) Aiming at the first-step reaction, diethoxymethane is innovatively adopted as a ring-closing reactant, and the two-step reaction of ring-closing reaction and methylation are combined into one step, so that the yield is high, and the reaction steps are reduced.
(3) The post-treatment of the product obtained by the three-step synthesis reaction does not need column chromatography separation, and the reaction product is directly separated out and dried.
(4) Compared with the existing synthetic route, the reaction steps are all more than 7 steps, the route has fewer reaction steps, is simple and convenient to separate, and improves the total yield and operability of the reaction.
Detailed Description
The following describes embodiments of the present invention in detail. The following examples are illustrative only and are not to be construed as limiting the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
EXAMPLE 1 Synthesis of Compound represented by formula 2
Compound 1(5.0g,12.87mmol) and CH were added at room temperature3CN (30mL) was mixed, stirred, and H was added slowly2O (5mL), diethoxymethane (1.41g,13.51mmol) is added, the mixture is heated and kept at 60 ℃ for reaction for 3 hours, then pyridine (2.036g,25.74mmol) is slowly added, the mixture is kept at 60 ℃ for reaction for 10 minutes, the reaction liquid is cooled to room temperature, a large amount of white solid appears in the reaction liquid, the compound shown in the formula 2 is obtained through suction filtration and drying, the white solid is obtained, the yield is 5.10g, the crude product yield is 96.1%, and the crude product is directly used for the next reaction without purification.
LC-MS(APCI):m/z=412.2(M+1)+。
Example 2 Synthesis of Compound represented by formula 2
Compound 1(5.0g,12.87mmol) and CH were added at room temperature3CN (30mL) was mixed, stirred, and H was added slowly2O (5mL), diethoxymethane (1.34g,12.87mmol) is added, the mixture is heated and kept at 55 ℃ for reaction for 3.5 hours, then pyridine (1.832g,23.16mmol) is slowly added, the mixture is kept at 55 ℃ for reaction for 15 minutes, the reaction liquid is cooled to room temperature, a large amount of white solid appears in the reaction liquid, the compound shown in the formula 2 is obtained through suction filtration and drying, the white solid is obtained, the yield is 4.81g, the yield of the crude product is 90.6%, and the crude product is directly used for the next reaction without purification.
EXAMPLE 3 Synthesis of Compound represented by formula 2
Compound 1(5.0g,12.87mmol) and CH were added at room temperature3CN (30mL) was mixed, stirred, and H was added slowly2O (5mL), diethoxymethane (1.61g,15.46mmol) is added, the mixture is heated and kept at 65 ℃ for reaction for 2.5 hours, then pyridine (2.55g,32.23mmol) is slowly added, the mixture is kept at 65 ℃ for reaction for 8 minutes, the reaction liquid is cooled to room temperature, a large amount of white solid appears in the reaction liquid, the compound shown in the formula 2 is obtained through suction filtration and drying, the white solid is obtained, the yield is 4.91g, the crude product yield is 92.5%, and the crude product is directly used for the next reaction without purification.
Example 4 Synthesis of Compound represented by formula 3
Compound 2(3.5g,8.482mmol) was added to THF (35mL) at room temperature with stirring, a 2M LiOH solution containing LiOH (366mg,15.27mmol) was slowly added thereto, the temperature was raised to 40 ℃ and the reaction was stirred for 2h, after completion of the reaction, the reaction mixture was cooled to room temperature, THF was removed under reduced pressure, 2M dilute hydrochloric acid was slowly added to adjust the pH to 6, suction filtration was performed, and drying was performed to obtain the compound represented by formula 3 as a white solid, 3.20g was obtained, the yield was 94.7%, and the HPLC purity was 98.3%.
LC-MS(APCI):m/z=398.2(M+1)+。
EXAMPLE 5 Synthesis of Compound represented by formula 3
Compound 2(3.5g,8.482mmol) was added to THF (35mL) at room temperature with stirring, a 2M LiOH solution containing LiOH (407mg,17mmol) was slowly added thereto, the temperature was raised to 45 ℃ and the reaction was stirred for 1.5h, after completion of the reaction, the reaction solution was cooled to room temperature, THF was removed under reduced pressure, 2M dilute hydrochloric acid was slowly added to adjust the pH to 6, suction filtration was performed, and drying was performed to obtain the compound represented by formula 3 as a white solid in an amount of 3.10g, yield 91.7%, and HPLC purity 98.0%.
EXAMPLE 6 Synthesis of Compound represented by formula 3
Compound 2(3.5g,8.482mmol) was added to THF (35mL) at room temperature with stirring, a 2M LiOH solution containing LiOH (467mg,19.51mmol) was slowly added thereto, the reaction was stirred at 36 ℃ for 2.5 hours, after completion of the reaction, the reaction mixture was cooled to room temperature, THF was removed under reduced pressure, 2M dilute hydrochloric acid was slowly added to adjust pH to 6, suction filtration was performed, and drying was performed to obtain the compound represented by formula 3 as a white solid, which was 3.01g, yield 89.0%, and HPLC purity 98.2%.
EXAMPLE 7 Synthesis of Compound of formula I
Mixing and stirring compound 3(2.0g,5mmol), compound 4(424mg,5.5mmol) and DMF (20mL) at room temperature, adding DIPEA (775.5mg,6mmol) dropwise, stirring at room temperature for reaction for 2H, cooling the reaction solution to room temperature after the reaction is finished, and adding H2And O (60mL), stirring for 10min, performing suction filtration, pulping and washing a filter cake by using an appropriate amount of acetone, and filtering and drying the filter cake to obtain the compound shown in the formula I, wherein the white solid is a white solid, the yield is 2.10g, and the HPLC purity is 99.6%.
LC-MS(APCI):m/z=457.2(M+1)+。
EXAMPLE 8 Synthesis of Compound of formula I
Mixing and stirring compound 3(2.0g,5mmol), compound 4(385mg,5mmol) and DMF (20mL) at room temperature, adding DIPEA (646mg,5mmol) dropwise, stirring and reacting at room temperature for 1.5H, cooling the reaction solution to room temperature after the reaction is finished, adding H2And O (60mL), stirring for 10min, performing suction filtration, pulping and washing a filter cake by using an appropriate amount of acetone, filtering and drying the filter cake to obtain the compound shown in the formula I, wherein the white solid is a white solid, the yield is 1.97g, and the HPLC purity is 99.7%.
EXAMPLE 9 Synthesis of Compound of formula I
Mixing and stirring compound 3(2.0g,5mmol), compound 4(462mg,6mmol) and DMF (20mL) at room temperature, adding DIPEA (969mg,7.5mmol) dropwise, stirring and reacting at room temperature for 2.5H, cooling the reaction solution to room temperature after the reaction is finished, and adding H2And O (60mL), stirring for 10min, performing suction filtration, pulping and washing a filter cake by using an appropriate amount of acetone, and filtering and drying the filter cake to obtain the compound shown in the formula I, wherein the white solid is a white solid, the yield is 2.01g, the yield is 87.6%, and the HPLC purity is 99.3%.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (10)
1. A method for synthesizing sematinib, comprising:
(1) contacting a compound represented by formula 1 with diethoxymethane, and pyridine, so as to obtain a compound represented by formula 2;
(2) contacting the compound represented by formula 2 with LiOH to obtain a compound represented by formula 3;
(3) contacting the compound shown as the formula 3 with the compound shown as the formula 4 so as to obtain the compound of the formula I, namely the sematinib.
2. The method according to claim 1, wherein in step (1), the following steps are included: at room temperature, compound 1 and CH3CN is mixed, stirred and H is slowly added2And O, adding diethoxymethane, heating to keep the temperature at 55-65 ℃ for reacting for 2.5-3.5 hours, then slowly adding pyridine, continuously keeping the temperature at 55-65 ℃ for reacting for 8-15 min, cooling the reaction liquid to room temperature, allowing a large amount of white solid to appear in the reaction liquid, performing suction filtration and drying to obtain the compound shown in the formula 2, wherein the compound shown in the formula 2 can be directly used for the next reaction without purification.
3. The method according to claim 2, wherein in step (1), the molar ratio of the compound represented by formula 1 to diethoxymethane and pyridine is 1: (1.0-1.2): (1.8-2.5).
4. The method according to claim 2, wherein in step (1), the molar ratio of the compound represented by formula 1 to diethoxymethane and pyridine is 1: 1.05: 2.
5. the method of claim 1, wherein in step (2), the following steps are included: adding a compound 2 into THF (tetrahydrofuran) at room temperature under a stirring state, slowly adding a LiOH solution, heating to 36-45 ℃, stirring for reaction, cooling the reaction solution to room temperature after the reaction is finished, removing THF (tetrahydrofuran) under reduced pressure, slowly adding dilute hydrochloric acid to adjust the pH value to 6, performing suction filtration, and drying to obtain a compound shown in a formula 3;
optionally, in the step (2), the compound shown in the formula 2 is contacted with LiOH at the temperature of 36-45 ℃, and the mixture is stirred and reacts for 1.5-2.5 hours;
optionally, in the step (2), the compound shown in the formula 2 is contacted with LiOH at 40 ℃, and the reaction is stirred for 2 hours;
6. the method according to claim 5, wherein in the step (2), the molar ratio of the compound represented by the formula 2 to LiOH is 1: (1.8 to 2.3), preferably the molar ratio of the compound represented by the formula 2 to LiOH is 1: 2.
7. the method of claim 1, wherein in step (3), the following steps are included: at room temperature, uniformly mixing and stirring the compound 3, the compound 4 and DMF, then dropwise adding N, N-Diisopropylethylamine (DIPEA), keeping at room temperature, stirring for reaction, cooling the reaction liquid to room temperature after the reaction is finished, and adding H2And O, stirring for 10min, then carrying out suction filtration, pulping and washing a filter cake by using an appropriate amount of acetone, and then filtering and drying the filter cake to obtain the compound shown in the formula I.
8. The method according to claim 7, wherein in the step (3), the compound represented by the formula 3 is contacted with the compound represented by the formula 4 and DIPEA at room temperature, and the reaction is carried out for 1.5 to 2.5 hours with stirring; preferably, the compound shown as the formula 3 is contacted with the compound shown as the formula 4 and DIPEA at room temperature, and the reaction is stirred for 2 hours;
optionally, in step (3), the molar ratio of the compound of formula 3 to the compound of formula 4 and DIPEA is 1: (1.0-1.2): (1.0-1.5);
optionally, in step (3), the molar ratio of the compound of formula 3 to the compound of formula 4 and DIPEA is 1:1.1: 1.2.
10. a method according to claims 1-9, characterized by the steps of:
(1) compound 1(5.0g,12.87mmol) and CH were added at room temperature3CN (30mL) was mixed, stirred, and H was added slowly2O (5mL), then adding diethoxymethane (1.41g,13.51mmol), heating and keeping the temperature at 60 ℃ for reaction for 3 hours, then slowly adding pyridine (2.036g,25.74mmol), keeping the temperature at 60 ℃ for reaction for 10 minutes, cooling the reaction liquid to room temperature, allowing a large amount of white solid to appear in the reaction liquid, performing suction filtration and drying to obtain a compound shown as a formula 2, wherein the white solid is 5.1g, the yield of a crude product is 96.1%, and the crude product is directly used for the next reaction without purification;
(2) adding compound 2(3.5g,8.482mmol) into THF (35mL) at room temperature under stirring, slowly adding a 2M LiOH solution containing LiOH (407mg,17mmol), heating to 40 ℃, stirring for reaction for 2h, after the reaction is completed, cooling the reaction solution to room temperature, removing THF under reduced pressure, slowly adding 2M dilute hydrochloric acid to adjust pH to 6, performing suction filtration, and drying to obtain the compound represented by formula 3 as a white solid, with a yield of 3.20g and 94.7%;
(3) mixing and stirring compound 3(2.0g,5mmol), compound 4(424mg,5.5mmol) and DMF (20mL) at room temperature, adding DIPEA (775.5mg,6mmol) dropwise, stirring at room temperature for reaction for 2H, cooling the reaction solution to room temperature after the reaction is finished, and adding H2And O (60mL), stirring for 10min, performing suction filtration, pulping and washing a filter cake by using an appropriate amount of acetone, and filtering and drying the filter cake to obtain the compound shown in the formula I, wherein the white solid is a white solid, the yield is 2.10g, and the HPLC purity is 99.6%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011643562.XA CN112759552A (en) | 2020-12-31 | 2020-12-31 | Synthesis method of semetinib |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011643562.XA CN112759552A (en) | 2020-12-31 | 2020-12-31 | Synthesis method of semetinib |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112759552A true CN112759552A (en) | 2021-05-07 |
Family
ID=75698703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011643562.XA Pending CN112759552A (en) | 2020-12-31 | 2020-12-31 | Synthesis method of semetinib |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112759552A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1652776A (en) * | 2002-03-13 | 2005-08-10 | 阵列生物制药公司 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
CN101247806A (en) * | 2005-06-23 | 2008-08-20 | 阵列生物制药公司 | SnAr process for preparing benzimidazole compounds |
CN101663279A (en) * | 2007-01-19 | 2010-03-03 | 阿迪生物科学公司 | inhibitors of mek |
WO2018065924A1 (en) * | 2016-10-04 | 2018-04-12 | Sun Pharmaceutical Industries Limited | Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation |
WO2020212832A1 (en) * | 2019-04-16 | 2020-10-22 | Alembic Pharmaceuticals Limited | Process of preparation of benzimidazole compounds |
CN112679438A (en) * | 2020-12-31 | 2021-04-20 | 武汉九州钰民医药科技有限公司 | Process for the preparation of semetinib |
-
2020
- 2020-12-31 CN CN202011643562.XA patent/CN112759552A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1652776A (en) * | 2002-03-13 | 2005-08-10 | 阵列生物制药公司 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
CN101247806A (en) * | 2005-06-23 | 2008-08-20 | 阵列生物制药公司 | SnAr process for preparing benzimidazole compounds |
CN101663279A (en) * | 2007-01-19 | 2010-03-03 | 阿迪生物科学公司 | inhibitors of mek |
WO2018065924A1 (en) * | 2016-10-04 | 2018-04-12 | Sun Pharmaceutical Industries Limited | Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation |
WO2020212832A1 (en) * | 2019-04-16 | 2020-10-22 | Alembic Pharmaceuticals Limited | Process of preparation of benzimidazole compounds |
CN112679438A (en) * | 2020-12-31 | 2021-04-20 | 武汉九州钰民医药科技有限公司 | Process for the preparation of semetinib |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110950872A (en) | Method for preparing targeted anticancer drug avapritinib | |
CN114230576A (en) | Preparation method of Ruogeli | |
EP4293026A1 (en) | High-purity thienopyrimidine compound and preparation method therefor | |
CN110590635A (en) | Preparation method of levetiracetam and intermediate thereof | |
CN111072633A (en) | Preparation method of esomeprazole magnesium trihydrate | |
CN112679438A (en) | Process for the preparation of semetinib | |
CN112625038A (en) | Method for preparing Ripoctinib | |
CN112759552A (en) | Synthesis method of semetinib | |
CN115611908B (en) | Preparation method of pranoprofen | |
WO2020091632A1 (en) | Novel method for producing n,n'-bis[2-(1н-imidazol-4-yl)ethyl]malonamide | |
CN114014864B (en) | Preparation process of traasiril compound | |
CN111116477B (en) | Synthesis process of doramelamine | |
CN102548957A (en) | Method for producing threo-3-(3,4-dihydroxyphenyl)-L-serine | |
CN105461691B (en) | A kind of preparation method of Azelnidipine | |
CN110066233B (en) | Preparation method of mono-substituted amine compound | |
JP4833419B2 (en) | Production of cyclic acids | |
CN110698381A (en) | Method for synthesizing N- (benzyloxycarbonyl) succinimide by one-pot two-phase method | |
CN114230568B (en) | Preparation method of HER2 small molecule inhibitor picatinib | |
CN113024521B (en) | Method for preparing emtrictinib | |
CN111333552B (en) | Synthesis method of beta-benzo amino acid compound | |
CN114105801B (en) | Process for preparing Ac-AA-OR | |
CN112375031B (en) | Preparation method of cilnidipine | |
KR100877134B1 (en) | Process for preparation of Acamprosate Calcium | |
CN112961090A (en) | Key intermediate for synthesizing Alpelisib and preparation method thereof | |
KR100515591B1 (en) | METHOD FOR PREPARING OF 4[(N-(tert-butoxycarbonyl)amino)methylene]-1-N-(tert-butoxycarbonyl)pyrrolidine-3-one |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210507 |
|
RJ01 | Rejection of invention patent application after publication |